JP2022521486A5 - - Google Patents

Info

Publication number
JP2022521486A5
JP2022521486A5 JP2021547309A JP2021547309A JP2022521486A5 JP 2022521486 A5 JP2022521486 A5 JP 2022521486A5 JP 2021547309 A JP2021547309 A JP 2021547309A JP 2021547309 A JP2021547309 A JP 2021547309A JP 2022521486 A5 JP2022521486 A5 JP 2022521486A5
Authority
JP
Japan
Prior art keywords
sequence number
sequence
transposase
cells
pair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017283 external-priority patent/WO2020163755A1/en
Publication of JP2022521486A publication Critical patent/JP2022521486A/ja
Publication of JP2022521486A5 publication Critical patent/JP2022521486A5/ja
Pending legal-status Critical Current

Links

JP2021547309A 2019-02-08 2020-02-07 トランスポゾンに基づく免疫細胞の改変 Pending JP2022521486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962803142P 2019-02-08 2019-02-08
US62/803,142 2019-02-08
PCT/US2020/017283 WO2020163755A1 (en) 2019-02-08 2020-02-07 Transposon-based modifications of immune cells

Publications (2)

Publication Number Publication Date
JP2022521486A JP2022521486A (ja) 2022-04-08
JP2022521486A5 true JP2022521486A5 (https=) 2023-02-14

Family

ID=71947504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547309A Pending JP2022521486A (ja) 2019-02-08 2020-02-07 トランスポゾンに基づく免疫細胞の改変

Country Status (10)

Country Link
US (1) US20220170044A1 (https=)
EP (1) EP3920941A4 (https=)
JP (1) JP2022521486A (https=)
KR (1) KR20220030205A (https=)
CN (1) CN114502731A (https=)
AU (1) AU2020218546A1 (https=)
CA (1) CA3129263A1 (https=)
IL (1) IL285422A (https=)
SG (1) SG11202108665PA (https=)
WO (1) WO2020163755A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
EP4017530A4 (en) * 2019-08-21 2024-05-08 Board of Regents, The University of Texas System IMMUNE CELLS FOR ADOPTIVE CELL THERAPIES
KR20220062305A (ko) * 2019-09-16 2022-05-16 맥마스터 유니버시티 키메라 공자극 수용체 및 이의 방법 및 용도
EP4146798A4 (en) * 2020-05-04 2025-02-12 Saliogen Therapeutics, Inc. TRANSPOSITION-BASED THERAPIES
EP4221725A4 (en) * 2020-10-02 2025-01-15 The Regents Of The University Of California DNA CONSTRUCTS FOR IMPROVED T-CELL IMMUNOTHERAPY OF CANCER
WO2022087238A1 (en) * 2020-10-21 2022-04-28 Wisconsin Alumni Research Foundation Anti-apoptotic vector and method of using the same
CN115894706A (zh) * 2021-09-30 2023-04-04 北京康辰药业股份有限公司 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用
AU2022381757A1 (en) * 2021-11-04 2024-05-09 Saliogen Therapeutics, Inc. Immune cells with chimeric antigen receptors or chimeric autoantibody receptors
WO2023081815A1 (en) * 2021-11-04 2023-05-11 Saliogen Therapeutics, Inc. Manufacturing of stem cells
JP2024541501A (ja) * 2021-11-25 2024-11-08 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ Ｃｄ９５ポリペプチド
US20250144211A1 (en) * 2022-02-07 2025-05-08 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
CN119486759A (zh) * 2022-02-14 2025-02-18 加利福尼亚大学董事会 用于改善t细胞免疫疗法的dna构建体
CN119343456A (zh) * 2022-03-15 2025-01-21 纽约基因组中心 用于改进型免疫疗法的方法和包括融合蛋白的组合物
WO2023178358A2 (en) * 2022-03-18 2023-09-21 Dna Twopointo, Inc. Modification of t cells
WO2024233669A2 (en) * 2023-05-11 2024-11-14 Saliogen Therapeutics, Inc. Compositions and methods for treatment of cystic fibrosis
WO2025235576A1 (en) * 2024-05-08 2025-11-13 Saliogen Therapeutics, Inc. Myotis lucifugus transposase engineering
CN121065098B (zh) * 2025-11-10 2026-04-17 浙江大学 一种stat3突变的细胞产品及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034956A1 (en) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Methods for modulating t cell survival by modulating bcl-xl protein level
US6143291A (en) * 1995-05-04 2000-11-07 Us Navy Methods for modulating T cell survival by modulating bcl-XL protein level
FR2736931B1 (fr) * 1995-07-17 1997-09-19 Univ Paris Curie Sequences regulatrices issues du gene cd4 et a expression specifique dans les lymphocytes t matures
WO2003089618A2 (en) * 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
WO2010085699A2 (en) * 2009-01-23 2010-07-29 The Johns Hopkins University Mammalian piggybac transposon and methods of use
US8592211B2 (en) * 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
MX370148B (es) * 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
US10344285B2 (en) * 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
US20170333480A1 (en) * 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
CA3001312A1 (en) * 2015-10-08 2017-04-13 Dna2.0, Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
CN109312361A (zh) * 2016-02-26 2019-02-05 波赛伊达治疗学股份有限公司 转座子系统及应用方法
ES2912408T3 (es) * 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
JP7227912B2 (ja) * 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節
CN119409836A (zh) * 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途

Similar Documents

Publication Publication Date Title
JP2022521486A5 (https=)
Glöckner et al. Identification and characterization of a new conjugation/type IVA secretion system (trb/tra) of Legionella pneumophila Corby localized on two mobile genomic islands
JP2023055884A5 (https=)
Cioffi et al. Chromosome spreading of associated transposable elements and ribosomal DNA in the fish Erythrinus erythrinus. Implications for genome change and karyoevolution in fish
JP2020518276A5 (https=)
JP2018534950A5 (https=)
Keng et al. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR
JP2008532477A5 (https=)
JP2021153588A5 (https=)
JP2020504709A5 (https=)
JP2017535552A5 (https=)
JP2019500899A (ja) ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作
JP2008538183A5 (https=)
JP2015518714A5 (https=)
JP2023541457A5 (https=)
JP2021525549A5 (https=)
US20220160870A1 (en) Neoantigen engineering using splice modulating compounds
Yang et al. Assignment [sup 1] of the human reticulon 4 gene (RTN4) to chromosome 2p14→ 2p13 by radiation hybrid mapping.
JP2005511023A5 (https=)
CN113584027B (zh) 一种激活p21基因表达的方法
Din et al. The nucleotide sequence at the transcription termination site of the ribosomal RNA gene in Tetrahymena thermophila
Patel et al. A replication initiator protein enhances the rate of hybrid formation between a silencer RNA and an activator RNA
JP2006501465A5 (https=)
JP2004512021A5 (https=)
CN117625621A (zh) 一种靶向敲除wnt5a基因的质粒及其制备方法与应用